| Age, years (SD) |
76.2 (8.3) |
75.9 (8.5) |
0.743 |
| Females |
194 (79.2%) |
194 (79.2%) |
1.000 |
| Length of follow-up, years (SD) |
9.7 (6.7) |
10.4 (7.8) |
|
| Alive at the date of last follow-up (%) |
74 (30.2%) |
66 (26.9%) |
|
| Blood pressure Mean (SD) |
|
|
|
| [N=240 in GCA cohort; 241 in non-GCA cohort] |
|
|
|
| Systolic |
139.7 (20.5) |
140.8 (20.3) |
0.72 |
| Diastolic |
75.9 (11.2) |
76.2 (12.0) |
0.98 |
| Antihypertensive medication (%) |
107 (44.4%) |
127 (52.3%) |
0.08 |
| [N=241 in GCA cohort and 243 in non-GCA cohort] |
|
|
|
| Lipid Profile: |
|
|
|
| Total Cholesterol Mean (SD) |
209.1 (49.3) |
207.5 (42.3) |
0.88 |
| [N=84 in GCA cohort and 96 in non-GCA cohort] |
|
|
|
| HDL (SD) |
61.5 (17.1) |
55.3 (17.9) |
0.034 |
| [N=62 in GCA cohort and 65 in non-GCA cohort] |
|
|
|
| LDL (SD) |
113.1 (36.1) |
108.0 (31.8) |
0.45 |
| [N=59 in GCA cohort and 56 in non-GCA cohort] |
|
|
|
| Triglycerides (SD) |
124.2 (59.6) |
148.8 (77.5) |
0.029 |
| [N=76 in GCA cohort and 91 in non-GCA cohort] |
|
|
|
| Lipid-lowering medication (%) |
23 (9.6%) |
39 (16.1%) |
0.032 |
| [N=240 in GCA cohort and 242 in non-GCA cohort] |
|
|
|
| Chronic kidney disease (physician diagnosis) (%) |
12 (5.0%) |
7 (2.9%) |
0.24 |
| [N=242 in GCA cohort and 242 in non-GCA cohort] |
|
|
|
| Body mass index, kg/m2 (SD) |
25.2 (5.1) |
26.0 (5.3) |
0.12 |
| Obesity (BMI≥30 kg/m2) |
38 (15.5%) |
41 (16.7%) |
0.71 |
| Smoking status, ever |
97 (42.5%) |
103 (44.8%) |
0.63 |
| [N=228 in GCA cohort and 230 in non-GCA cohort] |
|
|
|
| Diabetes Mellitus |
17 (6.9%) |
40 (16.3%) |
0.001 |
| Framingham Risk Score % (SD) |
30.0 (18.6) |
34.1 (22.6) |
0.10 |
| [N=240 in GCA cohort and 241 in non-GCA cohort] |
|
|
|
| Framingham Risk Score (categorized) |
|
|
0.48 |
| Missing |
5 |
4 |
|
| <6% |
6 (2.5%) |
4 (1.7%) |
|
| 6-10% |
13 (5.4%) |
16 (6.6%) |
|
| 10-20% |
65 (27.1%) |
54 (22.4%) |
|
| 20-50% |
115 (47.9%) |
113 (46.9%) |
|
| >50% |
41 (17.1%) |
54 (22.4%) |
|
| Any Prior ACS |
18 (7.4%) |
17 (6.9%) |
0.86 |
